Finding the Best Treatment Options for Mycobacterium Abscessus Lung Disease to Improve Health and Reduce Side Effects
Led by The University of Queensland · Updated on 2026-05-11
300
Participants Needed
50
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Mycobacterium abscessus MABS is a group of rapidly growing bacteria resistant to many drugs, causing lung infections that can lead to serious health problems, decreased lung function, and higher risk during lung transplants. The prevalence of MABS infections is increasing globally despite the relatively small number of affected people. The Finding the Optimal Regimen for Mycobacterium abscessus Treatment FORMaT trial aims to identify the best treatment combinations to improve health outcomes while reducing side effects and treatment burden. It also seeks to develop biomarkers to guide treatment decisions and assess disease severity in patients with MABS pulmonary disease MABS-PD.
The trial is an ongoing, adaptive study designed to test and improve combinations of therapies for both children and adults with MABS-PD. Participants receive various drug treatments including intravenous therapies such as amikacin, tigecycline, cefoxitin or imipenem combined with oral antibiotics like azithromycin, clarithromycin, and clofazimine. The study includes phases of intensive intravenous therapy followed by consolidation therapy with oral andor inhaled antibiotics. Treatments can be adjusted based on tolerance and microbiological response, with new therapies added or removed as evidence evolves.
Participants are involved in screening, treatment, and follow-up visits extending up to 62 weeks. The study monitors microbiological clearance of infection alongside treatment tolerance. Assessments include lung function tests, chest CT scans, quality of life questionnaires, six-minute walk tests, and evaluation of treatment safety and resistance. Researchers also study health costs and reasons for early withdrawal. This comprehensive monitoring helps understand how treatments affect disease control, lung health, and patient well-being over time.
CONDITIONS
Brief Title
Finding the Optimal Regimen for Mycobacterium Abscessus Treatment
Research Team
C
Claire Wainwright, MD
K
Kara Brady, MPharm
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Australian Government Department of Health and Ageing
Collaborating Sponsor
Who Can Participate
All Ages
All Genders
Eligibility Criteria
You may qualify if you...
Diagnosis of Mycobacterium abscessus pulmonary disease meeting clinical, radiological, and microbiological criteria
Male or female participants of any age
No treatment for MABS pulmonary disease in the 12 months before eligibility assessment
Signed informed consent by participant or legal guardian if under 18
Ability to comply with study visits, therapies, and procedures as judged by the investigator
You will not qualify if you...
Currently receiving treatment for Mycobacterium abscessus infection, except azithromycin for routine cystic fibrosis or chronic pulmonary disease
QTc interval greater than 500 milliseconds
Pregnant or planning to breastfeed
Known allergy or contraindication to study therapies with no alternatives provided
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Intensive Therapy
Duration - Up to 12 weeks depending on response and randomization to short or prolonged intensive therapy
Participants receive intensive drug therapy with intravenous and/or inhaled antibiotics including amikacin, tigecycline, cefoxitin or imipenem, and oral azithromycin or clarithromycin combined with clofazimine. This phase aims to clear the MABS infection while monitoring for tolerance and adverse events.
Visits at screening, end of short intensive therapy (Week 6), and end of prolonged intensive therapy or Week 12 visit
Consolidation Therapy
Duration - Up to 44 to 50 weeks following intensive therapy, with an additional 4 weeks off treatment for final outcome assessment
Participants continue treatment with oral antibiotics including clofazimine, azithromycin or clarithromycin, and one to three additional oral antibiotics such as linezolid, co-trimoxazole, doxycycline, moxifloxacin, bedaquiline (adults only), or rifabutin to maintain infection clearance and achieve final treatment goals.
Visits continue through treatment and include final outcome visit at Week 56 or Week 62 depending on therapy duration
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
5
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Finding the optimal regimen for Mycobacteroides abscessus treatment (FORMaT) in people with Mycobacteroides abscessus pulmonary disease: a multicentre, randomised, multi-arm, adaptive platform trial.